Search
Abstract & Clinical Case Submission and Travel Grant
Abstract and clinical case procedureAbstract submission is closed
The official abstract submission closed on August 1, 2023 (23:59).
EU funding crucial in allowing medical researchers across member states to collaborate in the development of new treatments
In an article published in Science|Business, Prof.
Read moreMultiple Myeloma
The SWG Multiple Myeloma has traditionally been composed of members of the European Myeloma Network (EMN). EMN is a dedicated academic, non-profit organization for clinical research in multiple myeloma.
Read moreBoard
The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes.
Read moreDeadlines & Announcements
New announcements will be published as soon as new elements for the Congress Sponsor Program for EHA2025 are released.
Read moreGoCART coalition activities (CARTs and cellular therapies)
GoCART Clinical Case Discussion Series for Physicians - 4th edition
Panel: Dr. Sara Ghorashian, Dr. Peter Bader and Dr. Franco Locatelli along with moderator Dr.
EHA-EBMT 3rd European CAR T-cell Meeting (Virtual)
Dates: February 4-6, 2021
Chairs: H Einsele (EHA) & C Chabannon (EBMT)
For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT) jointly organized the European CAR T-cell Meeting; this year in…
Effective treatment of aging patients with hematological diseases discussed during SWG Aging meeting in Poland
The progress in the field of aging and the optimal and rational approaches of "fit" and "unfit" older patients with malignant hemopathies was the focus of the three-day EHA-SWG Scientific Meeting on Aging and Hematology held on October 12-14, 2018 in…
Read moreStopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- »